Ieramilimab
(Redirected from LAG525)
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | LAG525 |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Ieramilimab (development code LAG525) is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.[1]
Ieramilimab's first clinical trial is a Phase I in patients with various solid tumors, in combination with spartalizumab (PDR001), an anti-PD-1 monoclonal antibody has been completed.[2] Recruiting for a phase 2 study in combination with spartalizumab for the treatment of metastatic melanoma is underway.[3]
References
- ^ "Meet Novartis Management presentation, 17/18 June 2015" (PDF). Novartis. Retrieved 9 July 2015.
- ^ Clinical trial number NCT02460224 for "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies." at ClinicalTrials.gov
- ^ Clinical trial number NCT03484923 for "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM)" at ClinicalTrials.gov
Categories:
- Orphaned articles from July 2015
- All orphaned articles
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Experimental cancer drugs
- Monoclonal antibodies